Blog - Page 930 of 5700 - QualityStocks

ThursdayJul 21, 2022 9:00 am

With Fertilizer Prices, Climate Change, and Low Crop Yields Threatening the Rice Industry, FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) May Have a Relevant Zero Carbon Emission Solutions

The rice production industry is under an imminent threat due to increased demand and reduced crop yields With Thailand, the Philippines, and China all facing problems in rice production, a lot rides on the success of India’s rice crops, despite the uncertainty of monsoon and harvest season FuelPositive Corp. is currently developing proprietary green ammonia technology driving for on-site fertilizer production and zero carbon emissions The rice production industry faces multiple imminent threats worldwide, including rising fertilizer costs, climate change, and increased demand when crop yields seem to be declining. These threats pose a potential risk to food security and…

WednesdayJul 20, 2022 2:49 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unlocking ‘New Frontiers of Discovery’ with Kernel Flow

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various conditions, has announced preliminary data from a feasibility study using Kernel Flow. The results indicate that ketamine-induced changes in functional connectivity last for several days after administration of the substance. “Kernel Flow is the first easy-to-use, wearable device that collects and measures real-time brain activity before, during and after a psychedelic experience. Using the device, the study successfully measured the neuro-effect of ketamine over 11 days, confirming changes in functional connectivity that are consistent with current scientific research,” a recent article reads.…

WednesdayJul 20, 2022 2:41 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that its global clinical trial for a potentially pivotal brain cancer treatment will expand patient eligibility following an amendment to its protocol for the study. “CNS has been enrolling patients in its phase II clinical trial for novel drug candidate Berubicin, which has shown promise in fighting the aggressive brain cancer glioblastoma (‘GBM’),” explains a recent article. “The trial will compare Berubicin’s performance to the standard of care chemotherapy agent Lomustine, aiming to establish that Berubicin is at least as effective as Lomustine and potentially better because of Berubicin’s reported capacity to cross the…

WednesdayJul 20, 2022 2:31 pm

QualityStocksNewsBreaks – Eat Well Investment Group Inc.’s (CSE: EWG) (OTC: EWGFF) Portfolio ‘Well Positioned to Capture Global Pulse Demand’

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) has leveraged its management’s experience, collectively having financed and invested in early-stage venture companies for over 25 years, in the sourcing, financing and building successful companies. “We have laid a strong foundation within the Eat Well Group investment platform, and we are very enthusiastic about the trajectory of our portfolio. Our portfolio companies are well positioned to capture global pulse demand and accelerate the scale of their better-for-you consumer products for years to come,” said Marc Aneed, Eat Well’s director, president and CEO. A recent article discusses significant expected growth for the…

WednesdayJul 20, 2022 2:17 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. Two-time Olympic gold medalist Abby Wambach joins the latest podcast to speak on behalf of Odyssey Health, a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. “I had a unique,…

WednesdayJul 20, 2022 12:57 pm

QualityStocksNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Enters Strategic Partnership for Production of Vista(R)-X90 Lidar

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, today announced that it has selected Fabrinet (NYSE: FN), a leading provider of advanced precision optical and electronic manufacturing services, for the production of its Vista(R)-X90 lidar, which will be deployed in the industry’s largest ADAS lidar series production program. According to the update, Cepton selected Fabrinet for its deep expertise in advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services for the production of high-performance, proprietary assemblies of its Vista-X90 lidars. “At Cepton, our goal is to be the world’s go-to supplier of…

WednesdayJul 20, 2022 12:38 pm

QualityStocksNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Celebrates Third Recognition of Delic Labs’ Dr. Markus Roggen to Cannabis Scientist Power List

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, was named to the Cannabis Scientist Power List for the third consecutive year. Due to his commitment to creating a body of work on cannabis research that will have a positive, lasting effect on the industry, Dr. Roggen is consistently recognized as one of the most influential figures in the processing professionals category. Under Dr. Roggen’s leadership, Delic Labs will transfer its cannabis sector expertise and experience…

WednesdayJul 20, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pending Start of Human Nicotine Study, NIC-H22-1, Leveraging Fast-Growing Global Nicotine Pouches Market

Lexaria Bioscience Corp. expects the upcoming human nicotine study to produce evidence that its patented DehydraTECH(TM) technology can enhance oral-tissue absorption with reduced negative experiences Data collected from animal study NIC-A21-1 showed that DehydraTECH enhanced oral nicotine pouches delivered peak nicotine levels in the bloodstream of animals 10x to 20x faster than the control The global nicotine pouches market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, being one of the fastest growing segments in the nicotine industry Lexaria's pipeline addresses serious unmet patient or consumer needs with greater market potential, addressing…

WednesdayJul 20, 2022 9:45 am

Nowigence Inc. (NOWG) Makes Inroads in India, Announces Independent Growth Council

NOWG signs MOU creating a strategic business partnership that will deliver value in India’s growing CSR market India has made CSR obligatory, requiring top companies that meet specific requirements to spend 2% of their normal net benefits on CSR initiatives annually The company announces the creation of the Nowigence Independent Growth Council As evidence of its continued commitment to and progress toward becoming a gamechanger in the global data gathering and analysis space, Nowigence (OTCQB: NOWG) has made two key announcements. First, Nowigence signed a memorandum of understanding (“MOU”) with India-based EquiPPP Social Impact Technologies Ltd. (https://ibn.fm/NiyLD). Second, Nowigence has…

WednesdayJul 20, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Responds to Growing Concerns About Concussion Head Injuries with Drug Device in Clinical Trial

As awareness of the long-term hazards of concussive head injuries for young athletes has increased during the past decade, advocates and business enterprises have stepped up to improve coach responsiveness to players’ condition While efforts primarily focus on assessing injury, Odyssey Health Inc. is developing a product it hopes to become the first drug device with FDA approval for treating a concussed patient after injury Odyssey is enrolling patients in a Phase 1 human clinical trial after completing pre-clinical studies in laboratory animals The medical research company’s assets include treatments for patients who may have undiagnosed heart disease, patients choking…

Site Search

Company Search